sellWeak cluster of 310b5-1 plan
Iqbal J Hussain sold $80k of CNTA
General Counsel at Centessa Pharmaceuticals plc. 5,689 shares at an average of $14.00, traded Apr 25, 2025, filed Apr 29, 2025.
Warning score
4Value
$80k
5,689 shares
Holdings after
105,386
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +9Trade size$80k at market
- 0Share of holdings soldSold 5.2% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001847903-25-000061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | MOption exercise Ordinary Shares10b5-1 | +3,609 | $5.84 | $21k | 108,995 | Apr 29, 2025 |
| Apr 25, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -3,609 | $14.00 | $51k | 105,386 | Apr 29, 2025 |
| Apr 28, 2025 | MOption exercise Ordinary Shares10b5-1 | +2,080 | $5.84 | $12k | 107,466 | Apr 29, 2025 |
| Apr 28, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -2,080 | $14.01 | $29k | 105,386 | Apr 29, 2025 |
| Apr 25, 2025 | MOption exercise Share Option (right to buy)derivative10b5-1 | -3,609 | $0.00 | $0 | 305,950 | Apr 29, 2025 |
| Apr 28, 2025 | MOption exercise Share Option (right to buy)derivative10b5-1 | -2,080 | $0.00 | $0 | 303,870 | Apr 29, 2025 |
Related signals
Other insiders at Centessa Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Centessa Pharmaceuticals plc | Mario Alberto Accardi President, Orexin Program | $210k 15,000 shares | -6% | |
| 11Weak | Centessa Pharmaceuticals plc | Iqbal J Hussain General Counsel | $168k 12,000 shares | -10% | |
| 6Weak | Centessa Pharmaceuticals plc | Gregory M Weinhoff Chief Business Officer | $139k 10,000 shares | -8% | |
| 31Weak | Centessa Pharmaceuticals plc | Saurabh Saha Chief Executive Officer | $695k 55,000 shares | -20% | |
| 0Weak | Centessa Pharmaceuticals plc | Gregory M Weinhoff Chief Business Officer | $128k 10,000 shares | -8% | |
| 24Weak | Centessa Pharmaceuticals plc | Saurabh Saha Chief Executive Officer | $699k 55,000 shares | -20% | |
| 48Moderate | CNTAbuy Centessa Pharmaceuticals plc | Arjun Goyal director | $5.9M 462,585 shares | - | |
| 0Weak | Centessa Pharmaceuticals plc | Iqbal J Hussain General Counsel | $4,354 311 shares | -0% | |
| 21Weak | Centessa Pharmaceuticals plc | Gregory M Weinhoff Chief Business Officer | $160k 11,742 shares | -9% | |
| 46Moderate | Centessa Pharmaceuticals plc | Saurabh Saha Chief Executive Officer | $682k 55,000 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.